3DR Labs, an Accumen Company, Announces a New Partnership with Imbio to bring its AI-based Lung Imaging Technology to Health Systems Nationally

▴ 3DR Labs, an Accumen Company, Announces a New Partnership with Imbio to bring its AI-based Lung Imaging Technology to Health Systems Nationally
3DR Labs, an Accumen Company, announced that it is now offering an artificial intelligence (AI) solution for diagnosing chronic lung disease through a new partnership with Imbio.

Accumen is helping healthcare get better, faster. Today, 3DR Labs, an Accumen Company, announced that it is now offering an artificial intelligence (AI) solution for diagnosing chronic lung disease through a new partnership with Imbio. 3DR Labs customers will have access to Imbio’s AI imaging technology effective immediately.

Imbio transforms standard medical images into rich visual maps of a patient’s condition alongside quantitative reports that provide physicians with detailed data about the type and extent of abnormalities found. This technology helps physicians to identify issues that may not be immediately visible in the images, allowing them to make prompt, appropriate treatment decisions for their patients with chronic lung and thoracic conditions.

“We are excited to partner with Imbio to bring AI-powered algorithms for image analyses to 3DR’s hospital customers. As health system resources continue to be strained by the COVID-19 pandemic, critical conditions may, unfortunately, be missed by the human eye and not be diagnosed until the patient experiences a future exacerbation or readmission. Imbio’s technology provides radiologists with another powerful resource to ensure that the diagnosis occurs, and treatment begins, as early in the disease progression as possible,” said Dr. Rob Falk, chief medical officer at 3DR Labs.

3DR Labs is the largest, most-respected 3D medical post-processing lab in the nation with more than 900 hospital clients. 3DR Labs processes more than 300,000 scans per year through its AHRT trained radiologic technologists, all based in the United States. The lab is open 7 days a week, 24 hours a day, 365 days a year.

As part of Accumen’s continuing efforts to support hospitals and health systems nationally, it also regularly adds new resources to its COVID-19 Resource Center at https://accumen.com/covid-19/#accumenresponsetools. Resources include laboratory, imaging, and supply chain rapid response tools, as well as personal protective equipment and swab or saliva testing kits available for order through Accumen’s U.S.-based manufacturing partners.

 

About Imbio

Imbio is a leader in fully-automated AI image analysis for acute and chronic pulmonary and cardiothoracic conditions. Imbio's solutions transform the way patients are discovered, diagnosed, and treated, enabling physician productivity and more personalized care for patients. Imbio's solutions are fully automated, regulatory cleared, and available through our global partners.  

 

About Accumen Inc.

At Accumen, our focus is on helping healthcare get better, faster. Accumen is a technology-enabled organization that partners with hospitals, health systems, commercial laboratories, and payer clients, to provide strategic solutions and services that deliver sustainable performance improvements. Our offerings include lab and imaging transformation, consulting, supply chain optimization, lab outreach, 3D post-processing, patient blood management, test utilization, anemia management, and clinical data exchange. Accumen’s offerings enable our clients to achieve and exceed their cost, quality, and service targets, as well as deliver excellent patient care through evidence-based data and clinical decision support capabilities.

Tags : #3DRLabs #AccumenCompany #Accumen #Imbio #AI #chroniclungdisease #LungDisease #Diagnosing #AI-poweredalgorithms #COVID-19pandemic #DrRobFalk

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Sexual wellness superstore, Love Depot launches digital campaign to deliver every desireMarch 28, 2024
Recharge Your Life: Simple Ways to Boost Your Physical and Mental EnergyMarch 28, 2024
The Neurological Toll of Common Household Chemicals: Insights from Recent ResearchMarch 28, 2024
The Aging Puzzle: Decoding the Mechanisms of AgingMarch 28, 2024
The Double-Edged Sword of Kala-azar Treatment: Shedding Light on Eye ComplicationsMarch 28, 2024
FTCCI Launches Industry-Academia Connect to improve the employability of Engineering Graduates and address the growing demand for Talent in Emerging TechMarch 27, 2024
NTT and Olympus Begin World's First Joint Demonstration Experiment of Cloud Endoscopy SystemMarch 27, 2024
NTT and Olympus Begin World's First Joint Demonstration Experiment of Cloud Endoscopy SystemMarch 27, 2024
2nd Edition of IIFL JITO Ahimsa Run for peace & for non-violence to be held on 31st MarchMarch 27, 2024
Brij Hotels Announced 4 Million in Series A Funding March 27, 2024
Combatting Childhood Sedentariness: The Key to Preventing Premature Vascular DamageMarch 27, 2024
Crucial Findings: Unlocking Paths to Combat Ebola's DevastationMarch 27, 2024
Guarding Against Disease: The Crucial Role of Oral Hygiene in Preventive HealthcareMarch 27, 2024
Sanofi & Cipla announce exclusive distribution partnership to expand reach of CNS portfolio in IndiaMarch 26, 2024
Surmandal's Tribute to the Legends of Hindustani Classical MusicMarch 26, 2024
In Moscow, over 350,000 mammograms have been analyzed using artificial intelligence as part of the compulsory health insurance programMarch 26, 2024
Embark on a Creative Journey: "Kala For A Cause" Unveils Pottery Workshop Series March 26, 2024
Healthtech pioneer Aurora Innovation appoints new CEO – expands in Europe with service that streamlines patient-healthcare interactionMarch 26, 2024
In A Rare Feat, 45 YO Woman Walks Within 6 Hrs. Of Dual Robotic Surgery In A Single Operation At HCGMCCMarch 26, 2024
Improve Cancer Care through Automated CT Analysis: Oncoshield – CTMarch 26, 2024